NHS Offers New Menopause Relief for 500,000 Women

Half a million women across England just gained access to a life-changing treatment that could transform their daily lives during menopause.

The NHS now offers Veoza, a non-hormonal pill that stops hot flushes and night sweats by blocking specific nerve pathways in the brain. This matters because until now, women who couldn't take traditional hormone replacement therapy had almost no other options.

Hot flushes and night sweats affect millions of women in their 40s and 50s, disrupting sleep, concentration, relationships, and work performance. For most women, HRT provides relief through tablets, patches, or gels that replace falling estrogen levels.

But not everyone can take HRT safely. Women with conditions like deep vein thrombosis, pulmonary embolism, and certain cases of diabetes or heart disease have faced limited choices until now.

Veoza works differently from HRT by targeting the brain pathways that trigger these uncomfortable symptoms. Clinical trials showed it meaningfully reduced symptoms without using hormones.

The National Institute for Health and Care Excellence approved the drug after determining it provides good value for taxpayers while offering genuine relief. Helen Knight, director of medicines evaluation at NICE, said patients clearly expressed how difficult limited options have been.

Dr. Sue Mann, national clinical director in women's health for NHS England, called the news very welcome. She noted that menopause symptoms can affect every part of a woman's life.

The Bright Side

While this breakthrough helps hundreds of thousands of women, it represents something bigger. For years, menopause treatments lagged behind other health priorities, leaving women struggling through symptoms that society often dismissed.

This approval signals real change. Medical researchers are finally investing in understanding menopause better and developing diverse treatment options. Women now have choices that fit their individual health needs rather than suffering in silence.

The drug isn't perfect. Women with breast cancer, other estrogen-dependent cancers, or liver disease can't take it yet because those groups weren't included in clinical trials. However, some women who've completed breast cancer treatment may qualify depending on their situation.

HRT remains the first-line treatment because of its proven benefits and variety of forms. Most women will likely continue using it successfully.

But for those 500,000 women who needed another path, this daily pill offers something they haven't had before: genuine relief and control over their health during a challenging life transition.